There are currently no results that match your search, please try again.
There are currently no results that match your search, please try again.
Martin Wood and Adrian La Porta discuss how artificial intelligence could transform pharmaceutical manufacturing in this preview of Bryden Wood's Accelerate Pharmaceuticals event. The conversation explores reimagining quality control systems, creating feedback loops between patients and manufacturing, the potential for continuous manufacturing, and fundamental questions about people-centric versus data-centric pharmaceutical processes. The discussion examines whether AI can bridge the traditional gap between drug development and industrialisation.
Click the 'play button' above to watch the episode, or read our 5 Key Takeaways from this episode below...
Traditional pharmaceutical quality frameworks rely on static, locked-in parameters and standardisation precisely because our understanding of what's happening inside manufacturing processes is limited. Quality control through consistency is essentially an antidote to this lack of knowledge - a paradigm that AI could completely reverse.
Rather than quality being about always doing things the same way, AI could enable pharmaceutical manufacturers to truly know what's happening in every moment of the process through vast amounts of real-time data. This represents a fundamental shift from locked-down standardisation to comprehensive understanding and dynamic optimisation.
With wearable technology and advanced diagnostics generating vast amounts of patient data, AI could create feedback loops from drug use back to manufacturing that are currently non-existent or extremely slow. This integration could blur the boundaries between development, manufacturing, and healthcare delivery.
Traditional pharmaceutical facilities are designed around human ergonomics, batch sizes manageable by people, and material handling suited to manual processes. AI-enabled automation and robotics could fundamentally reshape facility architecture, potentially enabling smaller, more distributed, and more agile manufacturing operations.
Bridging the gap between drug development and manufacturing industrialisation requires unprecedented collaboration between big pharma, biotech, big tech, academia, regulators, and investors. The pharmaceutical industry's competitive nature makes this difficult, yet common standards and shared frameworks are essential to prevent dispersed, inefficient investment in AI solutions.
Watch Navigating the Energy Debate: Challenges and Solutions with Martin Wood, Adrian La Porta and John Dyson here
